Disease: Generalized Anxiety Disorder (GAD)

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

This comprehensive review explores how psychedelic drugs like psilocybin mushrooms, DMT, and LSD may offer new hope for treating depression, anxiety, and PTSD, especially for patients who don’t respond to conventional antidepressants. Historically used in spiritual ceremonies for thousands of years, these compounds are now being scientifically studied and show promise with fewer side effects than many traditional psychiatric medications. The authors emphasize that while results are encouraging, more research and regulatory approval are needed before these treatments become widely available in mainstream medicine.

Read More »

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models

This paper addresses confusion about how ketamine and psychedelics are being used to treat mental health conditions like depression and PTSD. The authors propose new clear definitions to distinguish whether these drugs are used alone for their chemical effects, combined with established talk therapies, or used to create experiences that are then processed in therapy. Using these clearer definitions will help patients, doctors, and regulators better understand what treatments involve and make more informed decisions.

Read More »

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis

This research examined how different types of psychological support during psilocybin treatment affect depression outcomes. Researchers analyzed 10 clinical trials involving 515 patients with depression. They found that whether therapists used structured manuals or flexible approaches, or whether therapy was directive or non-directive, the depression improvement from psilocybin treatment was similar across all approaches.

Read More »
Scroll to Top